TELA Bio Q2 FY26 net loss widens to $11.3 million; revenue drops 4% to $19.3 million - TELA News | RalliesTELA Bio Q2 FY26 net loss widens to $11.3 million; revenue drops 4% to $19.3 million
T
TELA• TELA Bio reports Q2 FY26 results
- TELA Bio posted Q2 revenue of $19.3 million, down 4% year over year on weaker OviTex PRS volumes.
- Net loss widened to $11.3 million; operating loss widened to $9.3 million.
- Gross margin rose 2 percentage points to 72% due to a tariff refund and a lower excess-and-obsolete inventory charge.
- International revenue climbed 26% year over year; OviTex unit volume rose 12% while LiquiFix revenue increased 39%.
- Heather Getz became CEO effective Aug. 4; TELA withdrew full-year 2026 revenue guidance while assessing strategy and cost alignment.
WHD
•
